Infliximab, adalimumab, certolizumab, or ustekinumab are approved in patients with Crohn’s disease; infliximab, adalimumab or ustekinumab are approved in patients with ulcerative colitis; IL-23 and IL-12/23 inhibitors are effective treatment option; Avoid IL-17 inhibitors. Here, IL17A is linked to Crohn disease.